- Insmed reported cash and cash equivalents of $1.28 billion in the second quarter of 2025, a 3% increase compared to the previous year, surpassing estimates of $875.7 million.
- The company’s reported loss per share was $1.70, an improvement from $1.94 loss per share in the previous year, but larger than the estimated loss of $1.29 per share.
- Research and Development (R&D) expenses rose by 21% year over year, totaling $177.2 million, which exceeded the estimated $162.6 million.
- Net product revenues grew by 19% from the previous year, reaching $107.4 million, slightly topping the estimate of $104.1 million.
- Selling, General, and Administrative (SG&A) expenses increased by 45% year over year to $154.8 million, slightly above the estimate of $152.2 million.
- Insmed received strong analyst support with 18 buy ratings and no holds or sells.
A look at Insmed Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Insmed Inc, a biopharmaceutical company specializing in innovative inhaled therapies for patients with rare lung diseases, has received a mixed outlook according to Smartkarma Smart Scores. With a strong momentum score of 5, the company is showing positive performance trends that indicate potential growth opportunities in the future. Additionally, a growth score of 3 suggests promising prospects for expansion and development within the industry. However, lower scores in value, dividend, and resilience indicate areas where the company may face challenges and need to focus on improvement to ensure long-term sustainability.
Insmed, Inc. is dedicated to addressing the unmet medical needs of patients with serious orphan lung diseases through its targeted inhaled therapies. While the company demonstrates high momentum and growth potential, areas such as value, dividend, and resilience require attention for better overall performance. Investors looking at Insmed Inc for long-term investment should consider the company’s strengths in innovation and market positioning, alongside its areas for improvement, to make informed decisions about its future prospects.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
